Opioid responsiveness in patients with neuroleptic-induced akathisia.
Identifieur interne : 005130 ( PubMed/Corpus ); précédent : 005129; suivant : 005131Opioid responsiveness in patients with neuroleptic-induced akathisia.
Auteurs : A. Walters ; W. Hening ; S. Chokroverty ; S. FahnSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1986.
English descriptors
- KwdEn :
- Acetaminophen (therapeutic use), Adult, Aged, Akathisia, Drug-Induced, Antipsychotic Agents (adverse effects), Codeine (therapeutic use), Dextropropoxyphene (therapeutic use), Female, Humans, Male, Middle Aged, Naloxone (adverse effects), Psychomotor Agitation (drug therapy), Receptors, Opioid (physiology).
- MESH :
- chemical , adverse effects : Antipsychotic Agents, Naloxone.
- chemical , physiology : Receptors, Opioid.
- chemical , therapeutic use : Acetaminophen, Codeine, Dextropropoxyphene.
- drug therapy : Psychomotor Agitation.
- Adult, Aged, Akathisia, Drug-Induced, Female, Humans, Male, Middle Aged.
Abstract
Five patients with either acute or tardive neuroleptic-induced akathisia (5 weeks to 1 1/2 years duration) were videotaped before, during, and after a 2-week trial of propoxyphene (Darvon), 100 mg q.i.d., or acetaminophen (Tylenol) with 30 mg codeine, two tabs, q.i.d. Three "blinded" observers, experienced in movement disorders, rated the involuntary movements shown on the videotapes and agreed that, on opioids, all patients showed substantial to complete improvement of their stereotyped restless akathitic movements. Matching placebo was not beneficial. One patient who had improved on opioids was challenged with naloxone while on the opioids. There was a brief but severe reactivation of the akathisia. Our results suggest that opioids offer a selective therapy for patients with neuroleptic-induced akathisia and further suggest that the endogenous opiate system may be involved in patients with neuroleptic-induced akathisia.
DOI: 10.1002/mds.870010206
PubMed: 2904116
Links to Exploration step
pubmed:2904116Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Opioid responsiveness in patients with neuroleptic-induced akathisia.</title><author><name sortKey="Walters, A" sort="Walters, A" uniqKey="Walters A" first="A" last="Walters">A. Walters</name><affiliation><nlm:affiliation>Department of Neurology, UMDNJ-Rutgers Medical School, New Brunswick 08903.</nlm:affiliation></affiliation></author><author><name sortKey="Hening, W" sort="Hening, W" uniqKey="Hening W" first="W" last="Hening">W. Hening</name></author><author><name sortKey="Chokroverty, S" sort="Chokroverty, S" uniqKey="Chokroverty S" first="S" last="Chokroverty">S. Chokroverty</name></author><author><name sortKey="Fahn, S" sort="Fahn, S" uniqKey="Fahn S" first="S" last="Fahn">S. Fahn</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1986">1986</date><idno type="RBID">pubmed:2904116</idno><idno type="pmid">2904116</idno><idno type="doi">10.1002/mds.870010206</idno><idno type="wicri:Area/PubMed/Corpus">005130</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Opioid responsiveness in patients with neuroleptic-induced akathisia.</title><author><name sortKey="Walters, A" sort="Walters, A" uniqKey="Walters A" first="A" last="Walters">A. Walters</name><affiliation><nlm:affiliation>Department of Neurology, UMDNJ-Rutgers Medical School, New Brunswick 08903.</nlm:affiliation></affiliation></author><author><name sortKey="Hening, W" sort="Hening, W" uniqKey="Hening W" first="W" last="Hening">W. Hening</name></author><author><name sortKey="Chokroverty, S" sort="Chokroverty, S" uniqKey="Chokroverty S" first="S" last="Chokroverty">S. Chokroverty</name></author><author><name sortKey="Fahn, S" sort="Fahn, S" uniqKey="Fahn S" first="S" last="Fahn">S. Fahn</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1986" type="published">1986</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetaminophen (therapeutic use)</term><term>Adult</term><term>Aged</term><term>Akathisia, Drug-Induced</term><term>Antipsychotic Agents (adverse effects)</term><term>Codeine (therapeutic use)</term><term>Dextropropoxyphene (therapeutic use)</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Naloxone (adverse effects)</term><term>Psychomotor Agitation (drug therapy)</term><term>Receptors, Opioid (physiology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antipsychotic Agents</term><term>Naloxone</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Receptors, Opioid</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Acetaminophen</term><term>Codeine</term><term>Dextropropoxyphene</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Psychomotor Agitation</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Akathisia, Drug-Induced</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Five patients with either acute or tardive neuroleptic-induced akathisia (5 weeks to 1 1/2 years duration) were videotaped before, during, and after a 2-week trial of propoxyphene (Darvon), 100 mg q.i.d., or acetaminophen (Tylenol) with 30 mg codeine, two tabs, q.i.d. Three "blinded" observers, experienced in movement disorders, rated the involuntary movements shown on the videotapes and agreed that, on opioids, all patients showed substantial to complete improvement of their stereotyped restless akathitic movements. Matching placebo was not beneficial. One patient who had improved on opioids was challenged with naloxone while on the opioids. There was a brief but severe reactivation of the akathisia. Our results suggest that opioids offer a selective therapy for patients with neuroleptic-induced akathisia and further suggest that the endogenous opiate system may be involved in patients with neuroleptic-induced akathisia.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">2904116</PMID><DateCreated><Year>1989</Year><Month>01</Month><Day>10</Day></DateCreated><DateCompleted><Year>1989</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>1</Volume><Issue>2</Issue><PubDate><Year>1986</Year></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Opioid responsiveness in patients with neuroleptic-induced akathisia.</ArticleTitle><Pagination><MedlinePgn>119-27</MedlinePgn></Pagination><Abstract><AbstractText>Five patients with either acute or tardive neuroleptic-induced akathisia (5 weeks to 1 1/2 years duration) were videotaped before, during, and after a 2-week trial of propoxyphene (Darvon), 100 mg q.i.d., or acetaminophen (Tylenol) with 30 mg codeine, two tabs, q.i.d. Three "blinded" observers, experienced in movement disorders, rated the involuntary movements shown on the videotapes and agreed that, on opioids, all patients showed substantial to complete improvement of their stereotyped restless akathitic movements. Matching placebo was not beneficial. One patient who had improved on opioids was challenged with naloxone while on the opioids. There was a brief but severe reactivation of the akathisia. Our results suggest that opioids offer a selective therapy for patients with neuroleptic-induced akathisia and further suggest that the endogenous opiate system may be involved in patients with neuroleptic-induced akathisia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Walters</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMDNJ-Rutgers Medical School, New Brunswick 08903.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hening</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Chokroverty</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Fahn</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D018848">Controlled Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011957">Receptors, Opioid</NameOfSubstance></Chemical><Chemical><RegistryNumber>362O9ITL9D</RegistryNumber><NameOfSubstance UI="D000082">Acetaminophen</NameOfSubstance></Chemical><Chemical><RegistryNumber>36B82AMQ7N</RegistryNumber><NameOfSubstance UI="D009270">Naloxone</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q830PW7520</RegistryNumber><NameOfSubstance UI="D003061">Codeine</NameOfSubstance></Chemical><Chemical><RegistryNumber>S2F83W92TK</RegistryNumber><NameOfSubstance UI="D011431">Dextropropoxyphene</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000082">Acetaminophen</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017109">Akathisia, Drug-Induced</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014150">Antipsychotic Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003061">Codeine</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011431">Dextropropoxyphene</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009270">Naloxone</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011595">Psychomotor Agitation</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011957">Receptors, Opioid</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1986</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1986</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1986</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2904116</ArticleId><ArticleId IdType="doi">10.1002/mds.870010206</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005130 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 005130 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:2904116
|texte= Opioid responsiveness in patients with neuroleptic-induced akathisia.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:2904116" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |